Maze Therapeutics, Inc.
MAZE$1.89B
Small CapNASDAQBiotechnology🇺🇸North America125 employees
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Sep 15, 2026
26wMarket Overview
Stock performance and key metrics
MAZE News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MZE829 | Phase 2 | Proteinuric Kidney Disease | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply